Phase 1B Trial: Evaluation of the Safety of Adding Brentuximab Vedotin to Low-Dose Total Skin Electron Beam (TSEB) for Treatment of Patients With Mycosis Fungoides and Sézary Syndrome

Trial Profile

Phase 1B Trial: Evaluation of the Safety of Adding Brentuximab Vedotin to Low-Dose Total Skin Electron Beam (TSEB) for Treatment of Patients With Mycosis Fungoides and Sézary Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 06 Dec 2016 Planned initiation date changed from 1 Nov 2016 to 1 Dec 2016.
    • 03 Nov 2016 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top